

I. AMENDMENT

In the Claims:

Please amend the claims as set forth in the following listing of claims, which will replace all prior versions and listings of claims in the application.

1-66. (Canceled)

67. (Previously Presented) A method of treating an ACE2 decreased state comprising administering to a mammal having an ACE2 decreased state a therapeutically effective amount of an ACE2 activator.

68. (Previously Presented) The method of claim 67, wherein the mammal is a human.

69. (Previously Presented) The method of claim 67, wherein the decreased ACE2 state is associated with hypertension, congestive heart failure, chronic heart failure, acute heart failure, myocardial infarction, arteriosclerosis, renal failure, and/or lung disease.

70-72. (Canceled)

73. (Previously Presented) The method of claim 67, further comprising administering to the mammal an effective amount of an ACE2 activator, wherein the ACE2 activator is co-administered with an ACE inhibitor.

74-97 (Canceled)

98. (New) The method of claim 67, wherein the ACE2 activator is an ACE2 polypeptide.

99. (New) The method of claim 67, wherein the ACE2 activator is nucleic acid encoding an ACE2 polypeptide.

100. (New) The method of claim 69, wherein the decreased ACE2 state is associated with a lung disease.

101. (New) The method of claim 100, wherein the lung disease is adult respiratory distress syndrome.
102. (New) The method of claim 100, wherein the lung disease is lung cancer.
103. (New) A method of treating an ACE2 decreased state comprising administering to a mammal having an ACE2 decreased state a therapeutically effective amount of an ACE2 polypeptide or a nucleic acid encoding an ACE2 polypeptide.